Is HRT safe now? What the FDA change and the experts actually say

"Is HRT safe now?" became a sharper question in November 2025, when the U.S. FDA moved to remove the decades-old boxed ("black box") warning from menopausal hormone therapy — specifically the warnings for cardiovascular disease, breast cancer, and probable dementia. The agency kept one warning: the endometrial-cancer risk of systemic estrogen taken without progesterone in women who still have a uterus. Label rewrites are rolling out over roughly six months, with new age-specific guidance noting benefits when therapy starts within about 10 years of menopause onset.

That regulatory shift is essentially the system catching up to what the experts in our dataset have argued for years. Peter Attia is the most emphatic: he calls the 2002 misinterpretation of the Women's Health Initiative (WHI) "one of the greatest missteps of medicine" and the resulting fear "completely overblown... propagated by people who are not familiar with the literature." His case: the WHI tested one regimen (conjugated equine estrogen plus a synthetic progestin) in an older cohort, and the breast-cancer headline was a relative-risk signal that translates to a very small absolute risk — roughly one extra case per 1,000 women per year — with estrogen-alone showing no increased breast-cancer risk.

Andrew Huberman reaches the same place mostly by hosting menopause specialists (Dr. Mary Claire Haver, Dr. Sara Gottfried), who lay out the timing window and the transdermal-over-oral preference; in his own solo voice he is more measured, flagging concerns around estrogen-dependent conditions. Mark Hyman supports HRT too, sequencing lifestyle first, then favoring bioidentical estradiol and micronized progesterone. Rhonda Patrick and Bryan Johnson don't take a substantive own-voice position, which is why the consensus score is 3.8 — strong among those who weigh in, rather than a unanimous five.

"Safe" is not the same as "right for everyone." The reassurance is strongest for healthy women starting near menopause onset; it does not erase the need for individualized care for women with a personal history of hormone-sensitive cancer, clotting disorders, or active liver disease. The decision — whether, which formulation, which route, what dose — belongs with a menopause-trained clinician.